HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiao-Feng Zhu Selected Research

excisanin A

11/2013A diterpenoid compound, excisanin A, inhibits the invasive behavior of breast cancer cells by modulating the integrin β1/FAK/PI3K/AKT/β-catenin signaling.
1/2013Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiao-Feng Zhu Research Topics

Disease

72Neoplasms (Cancer)
03/2022 - 02/2002
16Nasopharyngeal Carcinoma
01/2019 - 05/2002
14Hepatocellular Carcinoma (Hepatoma)
07/2021 - 06/2003
13Breast Neoplasms (Breast Cancer)
10/2021 - 08/2003
10Carcinogenesis
01/2021 - 08/2003
6Carcinoma (Carcinomatosis)
01/2022 - 04/2008
6Colonic Neoplasms (Colon Cancer)
06/2016 - 08/2005
6Osteosarcoma (Osteogenic Sarcoma)
05/2012 - 06/2004
6Leukemia
01/2011 - 02/2002
5Neoplasm Metastasis (Metastasis)
12/2021 - 06/2016
5Infections
09/2015 - 05/2011
4Lung Neoplasms (Lung Cancer)
10/2018 - 10/2009
3Hypertension (High Blood Pressure)
08/2021 - 04/2012
3Colorectal Neoplasms (Colorectal Cancer)
12/2019 - 10/2009
3Nasopharyngeal Neoplasms (Cancer of the Nasopharynx)
01/2018 - 12/2005
3Liver Neoplasms (Liver Cancer)
01/2018 - 12/2005
3Lymphoma (Lymphomas)
09/2015 - 02/2006
3Ovarian Epithelial Carcinoma
04/2013 - 06/2008
3Osteoporosis
04/2012 - 04/2005
2B-Cell Lymphoma (Lymphoma, B Cell)
03/2022 - 11/2015
2Alcoholism (Alcohol Abuse)
01/2022 - 01/2020
2Triple Negative Breast Neoplasms
11/2021 - 01/2020
2Stomach Neoplasms (Stomach Cancer)
01/2020 - 12/2005
2Thrombosis (Thrombus)
01/2020 - 09/2011
2Peripheral Nerve Injuries
12/2019 - 06/2018
2Anaplastic Thyroid Carcinoma
11/2019 - 08/2005
2Melanoma (Melanoma, Malignant)
01/2019 - 01/2019
2Adenocarcinoma of Lung
10/2018 - 12/2005
2Type 2 Diabetes Mellitus (MODY)
01/2017 - 05/2011
2End Stage Liver Disease
01/2017 - 05/2011
2Chronic Hepatitis B
12/2011 - 12/2011
2Massive Hepatic Necrosis
09/2011 - 06/2000
2Esophageal Squamous Cell Carcinoma
08/2011 - 02/2010
2Graft vs Host Disease (Graft-Versus-Host Disease)
05/2011 - 03/2011
2Acute Kidney Injury (Acute Renal Failure)
05/2011 - 10/2009
2Embolism (Embolus)
01/2010 - 01/2008

Drug/Important Bio-Agent (IBA)

16Proteins (Proteins, Gene)FDA Link
03/2022 - 04/2005
12Phosphotransferases (Kinase)IBA
01/2022 - 05/2005
8Beclin-1IBA
12/2021 - 06/2008
7Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2021 - 08/2003
6Cisplatin (Platino)FDA LinkGeneric
03/2022 - 07/2007
6Reactive Oxygen Species (Oxygen Radicals)IBA
10/2021 - 07/2010
6Pharmaceutical PreparationsIBA
07/2021 - 05/2002
6DNA (Deoxyribonucleic Acid)IBA
10/2018 - 12/2011
5Caspase 3 (Caspase-3)IBA
03/2022 - 02/2002
5Biomarkers (Surrogate Marker)IBA
01/2021 - 08/2011
5Messenger RNA (mRNA)IBA
01/2017 - 04/2005
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2017 - 05/2005
4TOR Serine-Threonine KinasesIBA
01/2017 - 08/2012
4Small Interfering RNA (siRNA)IBA
09/2015 - 02/2006
4hirsutanol AIBA
02/2013 - 07/2010
3Factor VII (Proconvertin)IBA
03/2022 - 06/2018
3Transcription Factors (Transcription Factor)IBA
03/2022 - 06/2018
3Biological ProductsIBA
01/2018 - 05/2012
3TransferasesIBA
01/2017 - 08/2005
3Topotecan (Hycamtin)FDA LinkGeneric
06/2016 - 10/2011
3Tyrosine Kinase InhibitorsIBA
07/2015 - 02/2007
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
03/2015 - 08/2012
3rhabdastrellic acid AIBA
08/2010 - 08/2007
3Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
10/2009 - 06/2008
3Etoposide (VP 16)FDA LinkGeneric
02/2008 - 06/2004
3manumycinIBA
08/2005 - 06/2003
2Ethanol (Ethyl Alcohol)IBA
01/2022 - 01/2021
2Brain-Derived Neurotrophic Factor (BDNF)IBA
01/2022 - 01/2020
26,7-dihydroxyflavoneIBA
01/2022 - 01/2021
2CytokinesIBA
10/2021 - 01/2016
2bafilomycin A1IBA
10/2021 - 01/2018
2Autophagy-Related Protein-1 HomologIBA
10/2021 - 08/2011
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
10/2021 - 08/2012
2alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2020 - 01/2017
2Immune Checkpoint InhibitorsIBA
01/2019 - 01/2019
2CateninsIBA
01/2018 - 11/2013
2Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
01/2017 - 08/2012
2Dasatinib (BMS 354825)FDA Link
11/2016 - 04/2013
2AntioxidantsIBA
06/2016 - 03/2013
2Doxorubicin (Adriamycin)FDA LinkGeneric
11/2015 - 03/2013
2N- (1- amino- 3- (2,4- dichlorophenyl)propan- 2- yl)- 2- (2- (methylamino)pyrimidin- 4- yl)thiazole- 5- carboxamideIBA
03/2015 - 08/2012
2dactolisibIBA
03/2015 - 01/2013
2LipidsIBA
03/2015 - 01/2012
2apogossypoloneIBA
09/2014 - 01/2011
2excisanin AIBA
11/2013 - 01/2013
2DiterpenesIBA
11/2013 - 04/2009
2SesquiterpenesIBA
02/2013 - 07/2010
2Mitogen-Activated Protein KinasesIBA
08/2012 - 04/2009
2ErbB-2 ReceptorIBA
05/2012 - 08/2003
2Capsules (Microcapsules)IBA
04/2012 - 04/2005
2Tacrolimus (Prograf)FDA LinkGeneric
03/2011 - 02/2008
2GossypolIBA
01/2011 - 08/2009
2CaspasesIBA
08/2010 - 02/2008
2Membrane Proteins (Integral Membrane Proteins)IBA
03/2010 - 06/2007
2LigandsIBA
12/2009 - 10/2009
2N'- (10H- indolo(3,2- b)quinolin- 11- yl)- N,N- dimethylpropane- 1,3- diamineIBA
12/2009 - 10/2009

Therapy/Procedure

13Liver Transplantation
08/2017 - 06/2000
11Therapeutics
10/2021 - 12/2007
6Drug Therapy (Chemotherapy)
01/2017 - 05/2002
4Immunotherapy
01/2022 - 01/2019
4Transplantation
01/2017 - 12/2010
4Aftercare (After-Treatment)
04/2012 - 01/2005
2Operative Time
01/2020 - 05/2011
2Hepatectomy
05/2011 - 12/2010